L
Lipum
Develops a biological drug for treatment of chronic inflammatory diseases
About Lipum
Lipum AB, headquartered in Umeå, Sweden, is an innovative biotech startup focused on developing groundbreaking treatments for chronic inflammatory disorders. The company is pioneering a novel approach to address these conditions, which include diseases like rheumatoid arthritis and Crohn's disease. Chronic inflammatory disorders are long-lasting conditions characterized by persistent inflammation, which can lead to severe health issues and significantly impact the quality of life.
Lipum's primary clientele includes healthcare providers, pharmaceutical companies, and patients suffering from chronic inflammatory diseases. The company operates within the global biopharmaceutical market, which is highly competitive and driven by the constant need for new and effective treatments.
The business model of Lipum revolves around research and development (R&D) of new therapeutic solutions. The company has successfully secured significant funding, including a €2.2 million grant from the European Commission's Horizon 2020 program. This financial support has been crucial in advancing their research and achieving key milestones.
Lipum generates revenue through multiple channels. Primarily, it aims to license its proprietary technology and treatments to larger pharmaceutical companies. Additionally, the company may enter into strategic partnerships and collaborations, which can provide upfront payments, milestone payments, and royalties based on the success of the developed treatments.
In summary, Lipum AB is a biotech startup dedicated to revolutionizing the treatment of chronic inflammatory disorders. By focusing on innovative R&D and leveraging strategic partnerships, the company is well-positioned to make a significant impact in the biopharmaceutical market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 71.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Inflammatory Diseases, Sustainable Development Goals, Biotech and Pharma, Hard Tech, Seal of Excellence EC, Horizon Europe
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2025 | $17M | $17M | Flerie Invest | ↗ |
| GRANT✓Other financing | Dec 2024 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Lipum is 2.9K monthly website visits, down 25.6% over the last three months. Lipum's team declined 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lipum in the Umeå kommun ecosystem
The Lipum office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
European Innovation Council
Vinnova
Series A1 investor entered at this stage
Series B and later1 investor entered at this stage
Flerie Invest
Other known investors2 additional known investors
Almi Företagspartner
Umeå Biotech Incubator
Source: Dealroom Talent Intelligence.
See Lipum’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










